Heart Failure
Conditions
Keywords
Chronic Fluid Overload
Brief summary
The purpose of this pilot study is to investigate the pharmacodynamic and pharmacokinetic parameters of a novel furosemide formulation administered subcutaneously as compared to oral furosemide.
Interventions
DRUGOral Furosemide tablets (80 mg)
Sponsors
scPharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Written informed consent obtained before any assessment is performed * Male and female subjects ≥18 years of age, with body weight \<120 kg and body mass index (BMI) \<30 kg/m2 * Female subjects must be at least 2 years post-menopausal * Participant must have been on oral furosemide (40 mg oid or bid) or therapeutic equivalent (bumetanide 1 mg oid or bid) for a period 90 days before the first dose of study medication * History of chronic heart failure according to 2012 ESC guidelines with presence of moderate symptoms of chronic fluid overload. Chronic fluid overload is defined as presence of stable signs and symptoms of heart failure and congestion, like dyspnea at mild exertion or minimal exertion, pulmonary congestion and/or peripheral edema at the time of presentation in combination with elevated levels on natriuretic peptides (NT-proBNP \> 300 ng/L) * In the opinion of the investigator, able to participate in the study
Exclusion criteria
* Acute Decompensated Heart Failure (ADHF) or recent history of ADHF or significant worsening in their HF symptoms (within prior 2 weeks) * Contraindication to furosemide * Systolic BP (SBP) \< 90 mm Hg * Temperature \> 38°C (oral or equivalent) or sepsis or active infection requiring i.v. anti-microbial treatment * Serum sodium \< 130 mmol/L and Serum potassium \< 3.0 mmol/L * Current or planned (throughout the completion of study drug infusion) treatment with any i.v. therapies, including inotropic agents, vasopressors, levosimendan, nesiritide or analogues; or mechanical support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device) * History of gastric or intestinal surgery that may affect absorption of oral medication * Presence or need for urinary catheterization * Current or planned ultrafiltration, hemofiltration, or dialysis * Impaired renal function defined as an estimated glomerular filtration rate (eGFR) on admission \< 30 mL/min/1.73 m2 will be calculated as per standard at local laboratory * Administration of intravenous radiographic contrast agent within 72 hours prior to screening or acute contrast-induced nephropathy at the time of screening * Major surgery within 30 days prior to screening * Administration of an investigational drug or implantation of investigational device, or participation in another trial, within 30 days before screening * Inability to follow instructions or comply with procedures * Any surgical or medical condition which in the opinion of the investigator may interfere with participation in the study or which may affect the outcome of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diuresis and natriuresis | 8 hours | Statistical summaries with a graphical presentation will show mean and individual diuresis and natriuresis time profiles such as time to first void, volume of first void, diuresis and natriuresis measured at 60 minute intervals up to 480 minutes following furosemide injection solution for subcutaneous administration or oral tablets. The diuretic response will be compared between therapies using t-tests or Wilcoxon test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Body Water Content | 8 hours | The correlation (Pearson coefficient) between bioimpedance (body water content) and diuresis will be investigated including bioimpedance measurement of fluid overload as a predictor diuretic response. |
| Pharmacokinetic profiles | 8 hours | A graphical presentation showing mean and individual plasma furosemide concentration-time profiles for comparison between subcutaneous or oral administration. Plasma furosemide concentration-time data will be analyzed using a non-compartmental method and population PK approach (non-linear mixed-effect model). Furosemide concentrations will be summarized using descriptive statistics (including N, mean, standard deviation (SD), coefficient of variation (CV%), median, minimum and maximum) for each treatment. |
| Cardiac Markers (NTpro-BNP, hs-Trop T, galectin-3) | 8 hours | Correlation methods to investigate interaction between cardiac makers (NTpro-BNP, hs-Trop T, galectin-3) and pharmacodynamic parameters (diuresis and natriuresis). |
| Dypsnea Scores on Visual Analog Scale and Likert Scale | 8 hours | Dyspnea score (Dyspnea Visual Analog Scale and Likert Scale), the New York Heart Association (NYHA) Functional Classification and thirst distress and grading assessments by subjects in response to subcutaneous or oral administration. |
| Injection site reaction on Draize Scale and Visual Analog Pain Scale | 8 hours | Visual inspection of injection site, 5-point Draize Scale and Visual Analog pain assessment recorded during subcutaneous administration. |
Countries
Netherlands
Outcome results
None listed